Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2011

Open Access 01-12-2011 | Research

Inhibition of interleukin-6 trans-signaling in the brain facilitates recovery from lipopolysaccharide-induced sickness behavior

Authors: Michael D Burton, Nathan L Sparkman, Rodney W Johnson

Published in: Journal of Neuroinflammation | Issue 1/2011

Login to get access

Abstract

Background

Interleukin (IL)-6 is produced in the brain during peripheral infection and plays an important but poorly understood role in sickness behavior. Therefore, this study investigated the capacity of soluble gp130 (sgp130), a natural inhibitor of the IL-6 trans-signaling pathway to regulate IL-6 production in microglia and neurons in vitro and its effects on lipopolysaccharide (LPS)-induced sickness behavior in vivo.

Methods

A murine microglia (BV.2) and neuronal cell line (Neuro.2A) were used to study the effects of stimulating and inhibiting the IL-6 signaling pathway in vitro. In vivo, adult (3-6 mo) BALB/c mice received an intracerebroventricular (ICV) injection of sgp130 followed by an intraperitoneal (i.p.) injection of LPS, and sickness behavior and markers of neuroinflammation were measured.

Results

Soluble gp130 attenuated IL-6- and LPS-stimulated IL-6 receptor (IL-6R) activation along with IL-6 protein release in both microglial (BV.2) and neuronal (Neuro.2A) cell types in vitro. Moreover, in vivo experiments showed that sgp130 facilitated recovery from LPS-induced sickness, and this sgp130-associated recovery was paralleled by reduced IL-6 receptor signaling, mRNA, and protein levels of IL-6 in the hippocampus.

Conclusions

Taken together, the results show that sgp130 may exert an anti-inflammatory effect on microglia and neurons by inhibiting IL-6 binding. These data indicate that sgp130 inhibits the LPS-induced IL-6 trans-signal and show IL-6 and its receptor are involved in maintaining sickness behavior.
Appendix
Available only for authorised users
Literature
1.
Maier SF, Goehler LE, Fleshner M, Watkins LR: The role of the vagus nerve in cytokine-to-brain communication. Neuroimmunomodulation. 1998, 840: 289-300.
2.
Quan N: Immune-to-brain signaling: How important are the blood-brain barrier-independent pathways?. Molecular Neurobiology. 2008, 37 (2-3): 142-152. 10.1007/s12035-008-8026-z.PubMedCentralCrossRefPubMed
3.
Ransohoff RM, Perry VH: Microglial Physiology: Unique Stimuli, Specialized Responses. Annual Review of Immunology. 2009, 27: 119-145. 10.1146/annurev.immunol.021908.132528.CrossRefPubMed
4.
Kelley KW, Bluthe RM, Dantzer R, Zhou JH, Shen WH, Johnson RW, Broussard SR: Cytokine-induced sickness behavior. Brain Behavior and Immunity. 2003, 17: S112-S118. 10.1016/S0889-1591(02)00077-6.CrossRef
5.
Abraham J, Johnson RW: Central inhibition of interleukin-1 beta ameliorates sickness behavior in aged mice. Brain Behavior and Immunity. 2009, 23 (3): 396-401. 10.1016/j.bbi.2008.12.008.CrossRef
6.
Combrinck MI, Perry VH, Cunningham C: Peripheral infection evokes exaggerated sickness behaviour in pre-clinical murine prion disease. Neuroscience. 2002, 112 (1): 7-11. 10.1016/S0306-4522(02)00030-1.CrossRefPubMed
7.
Godbout JP, Chen J, Abraham J, Richwine AF, Berg BM, Kelley KW, Johnson RW: Exaggerated neuroinflammation and sickness behavior in aged mice after activation of the peripheral innate immune system. Faseb Journal. 2005, 19 (7): 1329-+.PubMed
8.
Huang Y, Henry CJ, Dantzer R, Johnson RW, Godbout JP: Exaggerated sickness behavior and brain proinflammatory cytokine expression in aged mice in response to intracerebroventricular lipopolysaccharide. Neurobiology of Aging. 2008, 29 (11): 1744-1753. 10.1016/j.neurobiolaging.2007.04.012.PubMedCentralCrossRefPubMed
9.
Campbell IL, Abraham CR, Masliah E, Kemper P, Inglis JD, Oldstone MBA, Mucke L: Neurologic disease induced in transgenic mice by cerebral overexpression of Interleukin-6. Proceedings of the National Academy of Sciences of the United States of America. 1993, 90 (21): 10061-10065. 10.1073/pnas.90.21.10061.PubMedCentralCrossRefPubMed
10.
Chen J, Buchanan JB, Sparkman NL, Godbout JP, Freund GG, Johnson RW: Neuroinflammation and disruption in working memory in aged mice after acute stimulation of the peripheral innate immune system. Brain Behavior and Immunity. 2008, 22 (3): 301-311. 10.1016/j.bbi.2007.08.014.CrossRef
11.
Heyser CJ, Masliah E, Samimi A, Campbell IL, Gold LH: Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain. Proceedings of the National Academy of Sciences of the United States of America. 1997, 94 (4): 1500-1505. 10.1073/pnas.94.4.1500.PubMedCentralCrossRefPubMed
12.
Mines MA, Yuskaitis CJ, King MK, Beurel E, Jope RS: GSK3 Influences Social Preference and Anxiety-Related Behaviors during Social Interaction in a Mouse Model of Fragile X Syndrome and Autism. Plos One. 2010, 5: 3.CrossRef
13.
Sparkman NL, Johnson RW: Neuroinflammation Associated with Aging Sensitizes the Brain to the Effects of Infection or Stress. Neuroimmunomodulation. 2008, 15 (4-6): 323-330. 10.1159/000156474.PubMedCentralCrossRefPubMed
14.
Sparkman NL, Buchanan JB, Heyen JRR, Chen J, Beverly JL, Johnson RW: Interleukin-6 facilitates lipopolysaccharide-induced disruption in working memory and expression of other proinflammatory cytokines in hippocampal neuronal cell layers. Journal of Neuroscience. 2006, 26 (42): 10709-10716. 10.1523/JNEUROSCI.3376-06.2006.CrossRefPubMed
15.
Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L: Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochemical Journal. 1998, 334: 297-314.PubMedCentralCrossRefPubMed
16.
Kishimoto T, Akira S, Taga T: IL-6 receptor and mechanism of signal transduction. International Journal of Immunopharmacology. 1992, 14 (3): 431-438. 10.1016/0192-0561(92)90173-I.CrossRefPubMed
17.
Rosejohn S, Heinrich PC: Soluble receptors for cytokines and growth factors - generation and biological function. Biochemical Journal. 1994, 300: 281-290.CrossRef
18.
Jones SA, Richards PJ, Scheller J, Rose-John S: IL-6 transsignaling: The in vivo consequences. Journal of Interferon and Cytokine Research. 2005, 25 (5): 241-253. 10.1089/jir.2005.25.241.CrossRefPubMed
19.
Jostock T, Mullberg J, Ozbek S, Atreya R, Blinn G, Voltz N, Fischer M, Neurath MF, Rose-John S: Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. European Journal of Biochemistry. 2001, 268 (1): 160-167. 10.1046/j.1432-1327.2001.01867.x.CrossRefPubMed
20.
Diehl S, Rincon M: The two faces of IL-6 on Th1/Th2 differentiation. Molecular Immunology. 2002, 39 (9): 531-536. 10.1016/S0161-5890(02)00210-9.CrossRefPubMed
21.
Mudter J, Neurath MF: IL-6 signaling in inflammatory bowel disease: Pathophysiological role and clinical relevance. Inflammatory Bowel Diseases. 2007, 13 (8): 1016-1023. 10.1002/ibd.20148.CrossRefPubMed
22.
Jang S, Kelley KW, Johnson RW: Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proceedings of the National Academy of Sciences of the United States of America. 2008, 105 (21): 7534-7539. 10.1073/pnas.0802865105.PubMedCentralCrossRefPubMed
23.
Zorina Y, Iyengar R, Bromberg KD: Cannabinoid 1 receptor and interleukin-6 receptor together induce integration of protein kinase and transcription factor signaling to trigger neurite outgrowth. Journal of Biological Chemistry. 2010, 285 (2): 1358-1370. 10.1074/jbc.M109.049841.PubMedCentralCrossRefPubMed
24.
Henry CJ, Huang Y, Wynne A, Hanke M, Himler J, Bailey MT, Sheridan JF, Godbout JP: Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. Journal of Neuroinflammation. 2008, 5.
25.
Abraham J, Jang S, Godbout JP, Chen J, Kelley KW, Dantzer R, Johnson RW: Aging sensitizes mice to behavioral deficits induced by central HIV-1 gp120. Neurobiology of Aging. 2008, 29 (4): 614-621. 10.1016/j.neurobiolaging.2006.11.002.PubMedCentralCrossRefPubMed
26.
Berg BM, Godbout JP, Kelley KW, Johnson RW: alpha-Tocopherol attenuates lipopolysaccharide-induced sickness behavior in mice. Brain Behavior and Immunity. 2004, 18 (2): 149-157. 10.1016/S0889-1591(03)00113-2.CrossRef
27.
Krzyszton CP, Sparkman NL, Grant RW, Buchanan JB, Broussard SR, Woods J, Johnson RW: Exacerbated fatigue and motor deficits in interleukin-10-deficient mice after peripheral immune stimulation. American Journal of Physiology-Regulatory Integrative and Comparative Physiology. 2008, 295 (4): R1109-R1114. 10.1152/ajpregu.90302.2008.CrossRef
28.
Marz P, Otten U, Rose-John S: Neural activities of IL-6-type cytokines often depend on soluble cytokine receptors. European Journal of Neuroscience. 1999, 11 (9): 2995-3004. 10.1046/j.1460-9568.1999.00755.x.CrossRefPubMed
29.
Schobitz B, Pezeshki G, Pohl T, Hemmann U, Heinrich PC, Holsboer F, Reul J: Soluble Interleukin-6 (IL-6) receptor augments central effects of IL-6 in vivo. Faseb Journal. 1995, 9 (8): 659-664.PubMed
30.
Dreuw A, Radtke S, Pflanz S, Lippok BE, Heinrich PC, Hermanns HM: Characterization of the signaling capacities of the novel gp130-like cytokine receptor. Journal of Biological Chemistry. 2004, 279 (34): 36112-36120. 10.1074/jbc.M401122200.CrossRefPubMed
31.
Taga T, Kishimoto T: gp130 and the interleukin-6 family of cytokines. Annual Review of Immunology. 1997, 15: 797-819. 10.1146/annurev.immunol.15.1.797.CrossRefPubMed
32.
Jones SA, Rose-John S: The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex. Biochimica Et Biophysica Acta-Molecular Cell Research. 2002, 1592 (3): 251-263. 10.1016/S0167-4889(02)00319-1.CrossRef
33.
Dantzer R, Bluthe RM, Gheusi G, Cremona S, Laye S, Parnet P, Kelley KW: Molecular basis of sickness behavior. Molecular Mechanisms of Fever. Edited by: Kluger MJ, Bartfai T, Dinarello CA. 1998, 856: 132-138.
34.
Mizuguchi H, Mizuno H, Yasukawa K, Ishiguro T, Fukui K, Imanaka T, Takagi M: Enhanced signal transduction by a directly fused protein of interleukin-6 and its receptor. Journal of Bioscience and Bioengineering. 2001, 91 (3): 299-304. 10.1263/jbb.91.299.CrossRefPubMed
35.
Nancey S, Hamzaoui N, Moussata D, Graber I, Bienvenu J, Flourie B: Serum interleukin-6, soluble interleukin-6 receptor and Crohn's disease activity. Digestive Diseases and Sciences. 2008, 53 (1): 242-247. 10.1007/s10620-007-9849-6.CrossRefPubMed
36.
Laflamme N, Rivest S: Toll-like receptor 4: the missing link of the cerebral innate immune response triggered by circulating gram-negative bacterial cell wall components. Faseb Journal. 2001, 15 (1): 155-163. 10.1096/fj.00-0339com.CrossRefPubMed
37.
Modrell B, Liu JW, Miller H, Shoyab M: LIF and OSM directly interact with a soluble form of gp130, the IL-6 receptor signal-transducing subunit. Growth Factors. 1994, 11 (2): 81-91. 10.3109/08977199409001050.CrossRefPubMed
38.
Coles B, Fielding CA, Rose-John S, Scheller J, Jones SA, O'Donnell VB: Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo. American Journal of Pathology. 2007, 171 (1): 315-325. 10.2353/ajpath.2007.061078.PubMedCentralCrossRefPubMed
39.
McLoughlin RM, Jenkins BJ, Grail D, Williams AS, Fielding CA, Parker CR, Ernst M, Topley N, Jones SA: IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proceedings of the National Academy of Sciences of the United States of America. 2005, 102 (27): 9589-9594. 10.1073/pnas.0501794102.PubMedCentralCrossRefPubMed
40.
Richards PJ, Nowell MA, Horiuchi S, McLoughlin RM, Fielding CA, Grau S, Yamamoto N, Ehrmann M, Rose-John S, Williams AS, et al: Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis and Rheumatism. 2006, 54 (5): 1662-1672. 10.1002/art.21818.CrossRefPubMed
41.
Block ML, Zecca L, Hong JS: Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nature Reviews Neuroscience. 2007, 8 (1): 57-69. 10.1038/nrn2038.CrossRefPubMed
42.
Kreutzberg GW: Microglia: A sensor for pathological events in the CNS. Trends in Neurosciences. 1996, 19 (8): 312-318. 10.1016/0166-2236(96)10049-7.CrossRefPubMed
43.
Maier SF, Watkins LR: Cytokines for psychologists: Implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychological Review. 1998, 105 (1): 83-107.CrossRefPubMed
44.
Godbout JP, Berg BM, Kelley KW, Johnson RW: alpha-Tocopherol reduces lipopolysaccharide-induced peroxide radical formation and interleukin-6 secretion in primary murine microglia and in brain. Journal of Neuroimmunology. 2004, 149 (1-2): 101-109. 10.1016/j.jneuroim.2003.12.017.CrossRefPubMed
45.
Godbout JP, Berg GM, Krzyszton C, Johnson RW: alpha-Tocopherol attenuates NF kappa B activation and pro-inflammatory cytokine production in brain and improves recovery from lipopolysaccharide-induced sickness behavior. Journal of Neuroimmunology. 2005, 169 (1-2): 97-105. 10.1016/j.jneuroim.2005.08.003.CrossRefPubMed
46.
Swiergiel AH, Dunn AJ: The roles of IL-1, IL-6, and TNF alpha in the feeding responses to endotoxin and influenza virus infection in mice. Brain Behavior and Immunity. 1999, 13 (3): 252-265. 10.1006/brbi.1999.0565.CrossRef
47.
Abraham J, Johnson RW: Consuming a Diet Supplemented with Resveratrol Reduced Infection-Related Neuroinflammation and Deficits in Working Memory in Aged Mice. Rejuvenation Research. 2009, 12 (6): 445-453. 10.1089/rej.2009.0888.PubMedCentralCrossRefPubMed
48.
Berg BM, Godbout JP, Chen J, Kelley KW, Johnson RW: alpha-tocopherol and selenium facilitate recovery from lipopolysaccharide-induced sickness in aged mice. Journal of Nutrition. 2005, 135 (5): 1157-1163.PubMed
49.
Richwine AF, Godbout JP, Berg BM, Chen J, Escobar J, Millard DK, Johnson RW: Improved psychomotor performance in aged mice fed diet high in antioxidants is associated with reduced ex vivo brain interleukin-6 production. Brain Behavior and Immunity. 2005, 19 (6): 512-520. 10.1016/j.bbi.2004.12.005.CrossRef
50.
Ye SM, Johnson RW: Increased interleukin-6 expression by microglia from brain of aged mice. Journal of Neuroimmunology. 1999, 93 (1-2): 139-148. 10.1016/S0165-5728(98)00217-3.CrossRefPubMed
51.
Saebyeol J, Dilger RN, Johnson RW: Luteolin inhibits microglia and alters hippocampal-dependent spatial working memory in aged mice. Journal of Nutrition. 2010, 140 (10): 1892-1898. 10.3945/jn.110.123273. 140 (110)CrossRef
52.
Chen Q, Wang WC, Bruce R, Li H, Schleider DM, Mulbury MJ, Bain MD, Wallace PK, Baumann H, Evans SS: Central role of IL-6 receptor signal-transducing chain gp130 in activation of L-selectin adhesion by fever-range thermal stress. Immunity. 2004, 20 (1): 59-70. 10.1016/S1074-7613(03)00358-3.CrossRefPubMed
53.
Fielding CA, McLoughlin RM, McLeod L, Colmont CS, Najdovska M, Grail D, Ernst M, Jones SA, Topley N, Jenkins BJ: IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. Journal of Immunology. 2008, 181 (3): 2189-2195.CrossRef
54.
Atreya R, Finotto S, Mudter J, Mullberg J, Jostock T, Holtmann M, Kishimoto T, Galle PR, Rose-John S, Neurath MF: Blockade of IL-6 transsignaling abrogates established experimental colitis in mice by suppression of T cell resistance against apoptosis. Gastroenterology. 2000, 118 (4): 4803.CrossRef
Metadata
Title
Inhibition of interleukin-6 trans-signaling in the brain facilitates recovery from lipopolysaccharide-induced sickness behavior
Authors
Michael D Burton
Nathan L Sparkman
Rodney W Johnson
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2011
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/1742-2094-8-54

Other articles of this Issue 1/2011

Journal of Neuroinflammation 1/2011 Go to the issue

Research

Sinomenine inhibits microglial activation by Aβ and confers neuroprotection

Research

Myelin down-regulates myelin phagocytosis by microglia and macrophages through interactions between CD47 on myelin and SIRPα (signal regulatory protein-α) on phagocytes

Research

Pro-inflammatory gene expression in solid glioblastoma microenvironment and in hypoxic stem cells from human glioblastoma

Research

Selective adenosine A2Areceptor agonists and antagonists protect against spinal cord injury through peripheral and central effects

Research

Changes in interleukin-1 signal modulators induced by 3,4-methylenedioxymethamphetamine (MDMA): regulation by CB2 receptors and implications for neurotoxicity

Research

Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders